The latest market report published by Acute Market Reports “Global Antibacterial Drugs Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2021 - 2029,” the antibacterial drugs market was valued at USD 45,146.2 Mn in 2020, and is expected to reach USD 49,605.1 Mn by 2029, expanding at a CAGR of 1.15% from 2021 to 2029.
Browse the full report Antibacterial Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2021 – 2029 at https://www.acutemarketreports.com/report/antibacterial-drugs-market
Market Insights
Antibacterial drugs are derived from bacteria or molds or are synthesized de novo. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases. Antibacterial drugs have several mechanisms of action, including inhibiting cell wall synthesis, increasing cell membrane permeability, interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes. The alarming antibacterial-resistance crisis has penetrated the awareness of clinicians, researchers, policymakers, governments and the public at large. The key factors assisting the growth of antibacterial drugs market are mounting prevalence of infectious diseases, government support, and increased research and development activities. However, evolving drug-resistant species, launch of generics, and upcoming patent expirations are anticipated to restrict the growth of the global market through 2029. Globally, the rise in geriatric population is also being considered as one of the key growth factors as it will indirectly increase the demand for various antibacterial drugs. The demand for antibacterial drugs will continue to rise mainly due to increased prevalence of resistant species that demand development of innovative molecules.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Thus, future commercialization of these drugs during the forecast period 2021 – 2029 is anticipated to have a reflective impact on the growth of the overall antibacterial drugs market.
Key Market Movements:
